Lenalidomide Krka

Lenalidomide, the active ingredient in Lenalidomide Krka, is an immunomodulatory agent presented as a tablet for oral use. It treats multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma‑cell proliferation and dysplastic clones.

Multiple myeloma (initial therapy): improves progression‑free and overall survival in newly diagnosed patients. Multiple myeloma (relapsed/refractory): provides disease control when standard therapies have failed. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves blood counts.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia or leukopenia: markedly low blood counts requiring medical intervention. - Liver toxicity: elevated transaminases indicating hepatic injury.

Before initiating therapy, clinicians should assess baseline labs and patient risk factors. - Monitor blood counts: perform regular CBCs to detect cytopenias early. - Assess thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Contraindicated in pregnancy: teratogenic; ensure effective contraception. - Adjust for renal impairment: dose modifications may be needed based on creatinine clearance. - Store at below 25°C: keep in the original pack, protect from moisture.

Lenalidomide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise lenalidomide exposure. - Live vaccines: risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - NSAIDs: additive risk of gastrointestinal bleeding. - CYP inducers (e.g., rifampin): may reduce therapeutic levels.